• Mithra announces topline results for COVID-19 Phase II Study

    1 day ago

  • Donesta® Phase III: recruitment completion of American study and additional recruitment in the European study

    Wednesday September 22nd 2021

  • Precirix and IFE sign clinical trial manufacturing agreement

    Monday September 13th 2021

  • ExeVir announces first patient enrolled in phase 1b/2 clinical study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

    Wednesday September 1st 2021

  • Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004

    Monday August 30th 2021

  • Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017

    Wednesday July 28th 2021

  • Bone Therapeutics provides update on the progress of clinical studies

    Monday July 19th 2021

  • Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

    Thursday July 15th 2021

  • Your news here?

  • Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

    Thursday July 15th 2021

  • Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump® study (POSEIDON)

    Thursday July 1st 2021

  • Mithra completes recruitment of Covid-19 Phase II Study

    Thursday June 17th 2021


Strategic Partners